Evidence map›Paper›PMID 41629999›Full record

Observational studyVirology journal2026

Efficacy and Safety of Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate for Preventing Mother-to-Child Transmission of Hepatitis B in Treatment-Naïve mothers: An Observational Study.

Xueyao Yang, Jun Chen, Lihua Duan, Xuexuan Li, Weiting Cheng, Ying Chen, Yan Huang, Zebing Huang

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xueyao Yang *Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Jun Chen *Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Lihua DuanDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xuexuan LiDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Weiting ChengDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Ying ChenDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yan HuangDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China. drhyan@csu.edu.cn.
Zebing HuangDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China. huangabing0330@csu.edu.cn.

Funding

Hunan Provincial Natural Science Foundation of China 2023JJ30892Hunan Provincial Natural Science Foundation of China 2023JJ40927National Natural Science Foundation of China 82370635National Natural Science Foundation of China 82400733
6 · The paper itself

Abstract

backgroundMother-to-child transmission (MTCT) is the primary cause of hepatitis B virus (HBV) infection. Antiviral therapy is crucial to reduce MTCT for pregnant women with high viremia. Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are the first-line antiviral drugs for hepatitis B. This study aimed to evaluate the effectiveness and safety of TAF and TDF in preventing HBV MTCT among treatment-naïve mothers.

methodsA total of 290 pregnant women with HBsAg positive for > 6 months, and HBV DNA ≥ 2 × 10^5 IU/ml or HBeAg positive were enrolled. Mothers received either TDF or TAF therapy and newborns received hepatitis B immunoglobulin and recombinant yeast hepatitis B vaccine. MTCT was evaluated during a one-year follow-up period after birth.

results290 pregnant women (185 with TDF therapy and 105 with TAF therapy) and 296 newborns (190 in TDF group and 106 in TAF group) were included. Both TDF and TAF effectively deceased HBV DNA levels with no significant difference, and the MTCT rates in TDF group and TAF group were similarly low (1.08% vs. 0.95%, P > 0.05). Moreover, no congenital malformations or growth and developmental abnormalities in newborns were observed in either group. However, serum creatinine was significantly higher and eGFR decreased significantly when treated by TDF, whereas TAF showed no significant renal effects.

conclusionsBoth TAF and TDF are effective in preventing HBV MTCT, with comparable MTCT rates. However, TAF demonstrated superior renal safety, making it a preferable option for preventing HBV MTCT in treatment-naïve mothers.

Indexed as

Antiviral AgentsDNA, ViralHepatitis BInfectious Disease Transmission, VerticalPregnancy Complications, InfectiousTenofovirAdenineAdultAlanineFemaleHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansInfant, NewbornPregnancyAdenineAlanineAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensTenofovirtenofovir alafenamideChronic hepatitis BMother-to-child transmissionNucleos(t)ide analogueRetrospective studyTenofovirTenofovir alafenamide fumarate

Identifiers

PMID41629999
PMCPMC12955035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.